Ghaziabad Online

IgG4-Related Disease Market Size, Trends, Key Companies, Emerging Drugs and Epidemiology Forecast | Xencor, Bristol-Myer Squibb and Others

 Breaking News
  • No posts were found

IgG4-Related Disease Market Size, Trends, Key Companies, Emerging Drugs and Epidemiology Forecast | Xencor, Bristol-Myer Squibb and Others

April 15
01:21 2021
IgG4-Related Disease Market Size, Trends, Key Companies, Emerging Drugs and Epidemiology Forecast | Xencor, Bristol-Myer Squibb and Others

IgG4-Related Disease Market

IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory disease characterized by dense infiltration of IgG4-positive plasma cells in the affected tissue(s) with or without elevated plasma levels of IgG4. It is a chronic- fibroinflammatory disorder affecting a wide range of organs. Elevation of serum IgG4 concentrations and abundant infiltration of IgG4-expressing plasma cells are key diagnostic features of this autoimmune disease.

DelveInsight’s “IgG4-Related Disease Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the IgG4-Related Disease, historical and forecasted epidemiology as well as the IgG4-Related Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The IgG4-Related Disease market report also covers emerging drugs, current treatment practices, IgG4-Related Disease market size and share of the individual therapies, current and forecasted IgG4-Related Disease Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current IgG4-Related Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 


Get FREE sample copy at:


IgG4-Related Disease Market Key Facts

  • As per Delveinsight estimates, the total prevalent population of IgG4-Related Disease in the seven major markets was found to be 300,874 cases in 2017. While the total diagnosed prevalent population of IgG4-Related Disease in the seven major markets was found to be 204,818 cases in 2017
  • As per Delveinsight analysis in the EU5 countries, the total prevalent population of IgG4-Related Disease was found to be maximum in Germany with 26,291 cases, followed by France with 21,461 cases in 2017. While Spain had the lowest number of prevalent cases of CRC with 14,962 cases in 2017
  • In the United States, the total diagnosed prevalent population of Type I Autoimmune Pancreatitis (AIP) was found to be 42,735 in 2017. While the other IgG4-related diseases accounted for 123,950 cases in 2017.


Get FREE sample copy at:


Key Benefits of IgG4-Related Disease Market Report

  • IgG4-Related Disease market report provides an in-depth analysis of IgG4-Related Disease Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
  • The IgG4-Related Disease market report will help in developing business strategies by understanding the IgG4-Related Disease Market trends & developments, key players, and future market competition that will shape and drive the IgG4-Related Disease market in the upcoming years.
  • The IgG4-Related Disease market report covers IgG4-Related Disease market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the IgG4-Related Disease patient populationmarket drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


IgG4-Related Disease Market

IgG4-Related Disease market size is expected to increase during the forecast period owing to the launch of upcoming therapies.

The IgG4-Related Disease market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted IgG4-Related Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. 

The report gives a thorough detail of IgG4-Related Disease market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 


Get FREE sample copy at:


IgG4-Related Disease Epidemiology

The IgG4-Related Disease epidemiology section covers insights about historical and current IgG4-Related Disease patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted IgG4-Related Disease epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


As of now, there are no specific drugs available that cure the disease completely as the pathophysiology of the IgG4 related disease is not clear and still under research and development. However, few of the therapies for IgG4-Related Disease are currently in different stages of development that are expected to be launched in the coming future.

Some of IgG4-Related Disease Companies:
Bristol-Myer Squibb
And many others.


IgG4-Related Disease Therapies covered in the market include:
Obexelimab (XmAb5871)
And many more.


Get FREE sample copy at:


Table of Content

  1. Key Insights
  2. Executive Summary 
  3. IgG4-Related Disease Competitive Intelligence Analysis
  4. IgG4-Related Disease Market Overview at a Glance
  5. IgG4-Related Disease Disease Background and Overview
  6. IgG4-Related Disease Patient Journey
  7. IgG4-Related Disease Epidemiology and Patient Population
  8. IgG4-Related Disease Treatment Algorithm, Current Treatment, and Medical Practices
  9. IgG4-Related Disease Unmet Needs
  10. Key Endpoints of IgG4-Related Disease Treatment
  11. IgG4-Related Disease Marketed Products
  12. IgG4-Related Disease Emerging Therapies
  13. IgG4-Related Disease Seven Major Market Analysis
  14. Attribute Analysis
  15. IgG4-Related Disease Market Outlook (7 major markets)
  16. IgG4-Related Disease Access and Reimbursement Overview
  17. KOL Views on the IgG4-Related Disease Market.
  18. IgG4-Related Disease Market Drivers
  19. IgG4-Related Disease Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5